<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>AZD0780 - Comprehensive Drug Profile</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, sans-serif;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
            padding: 20px;
        }
        
        .container {
            max-width: 1400px;
            margin: 0 auto;
            background: white;
            border-radius: 20px;
            box-shadow: 0 20px 60px rgba(0,0,0,0.3);
            overflow: hidden;
        }
        
        .header {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 40px;
            position: relative;
            overflow: hidden;
        }
        
        .header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -10%;
            width: 40%;
            height: 200%;
            background: rgba(255,255,255,0.05);
            transform: rotate(45deg);
        }
        
        .drug-title {
            position: relative;
            z-index: 1;
        }
        
        .drug-name {
            font-size: 48px;
            font-weight: bold;
            margin-bottom: 10px;
            text-shadow: 2px 2px 4px rgba(0,0,0,0.2);
        }
        
        .drug-subtitle {
            font-size: 24px;
            opacity: 0.95;
            margin-bottom: 5px;
        }
        
        .drug-company {
            font-size: 20px;
            opacity: 0.9;
        }
        
        .status-badge {
            display: inline-block;
            background: rgba(255,255,255,0.2);
            padding: 8px 16px;
            border-radius: 20px;
            margin-top: 20px;
            font-weight: 600;
            backdrop-filter: blur(10px);
        }
        
        .nav-tabs {
            display: flex;
            background: #f8f9fa;
            border-bottom: 2px solid #e0e0e0;
            overflow-x: auto;
        }
        
        .nav-tab {
            padding: 15px 30px;
            cursor: pointer;
            border: none;
            background: transparent;
            font-size: 16px;
            font-weight: 600;
            color: #666;
            transition: all 0.3s;
            white-space: nowrap;
        }
        
        .nav-tab:hover {
            background: rgba(102, 126, 234, 0.1);
        }
        
        .nav-tab.active {
            color: #667eea;
            border-bottom: 3px solid #667eea;
            margin-bottom: -2px;
        }
        
        .content-area {
            padding: 40px;
        }
        
        .tab-content {
            display: none;
            animation: fadeIn 0.5s;
        }
        
        .tab-content.active {
            display: block;
        }
        
        @keyframes fadeIn {
            from { opacity: 0; transform: translateY(10px); }
            to { opacity: 1; transform: translateY(0); }
        }
        
        .mechanism-section {
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            border-radius: 15px;
            padding: 30px;
            margin-bottom: 30px;
        }
        
        .mechanism-title {
            font-size: 24px;
            color: #333;
            margin-bottom: 20px;
            display: flex;
            align-items: center;
        }
        
        .mechanism-icon {
            width: 40px;
            height: 40px;
            background: #667eea;
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 15px;
            color: white;
            font-weight: bold;
        }
        
        .mechanism-content {
            line-height: 1.8;
            color: #555;
        }
        
        .mechanism-highlight {
            background: rgba(102, 126, 234, 0.1);
            padding: 2px 6px;
            border-radius: 4px;
            font-weight: 600;
            color: #667eea;
        }
        
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 20px;
            margin-top: 20px;
        }
        
        .dosing-card {
            background: white;
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            transition: all 0.3s;
        }
        
        .dosing-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
            border-color: #667eea;
        }
        
        .dosing-label {
            font-size: 14px;
            color: #888;
            margin-bottom: 5px;
        }
        
        .dosing-value {
            font-size: 24px;
            font-weight: bold;
            color: #333;
        }
        
        .dosing-detail {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .timeline-container {
            margin: 30px 0;
            padding: 30px;
            background: #f8f9fa;
            border-radius: 15px;
        }
        
        .timeline-header {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 30px;
            color: #333;
        }
        
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 50%;
            top: 0;
            bottom: 0;
            width: 3px;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
        }
        
        .timeline-item {
            position: relative;
            margin-bottom: 40px;
            display: flex;
            align-items: center;
        }
        
        .timeline-item:nth-child(odd) {
            flex-direction: row-reverse;
        }
        
        .timeline-content {
            width: 45%;
            background: white;
            padding: 20px;
            border-radius: 10px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .timeline-content:hover {
            transform: scale(1.02);
            box-shadow: 0 10px 30px rgba(0,0,0,0.15);
        }
        
        .timeline-dot {
            position: absolute;
            left: 50%;
            transform: translateX(-50%);
            width: 20px;
            height: 20px;
            background: #667eea;
            border: 4px solid white;
            border-radius: 50%;
            box-shadow: 0 2px 10px rgba(0,0,0,0.2);
            z-index: 1;
        }
        
        .timeline-date {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 5px;
        }
        
        .timeline-title {
            font-size: 16px;
            font-weight: 600;
            margin-bottom: 5px;
        }
        
        .timeline-description {
            font-size: 14px;
            color: #666;
            line-height: 1.5;
        }
        
        .timeline-details {
            display: none;
            margin-top: 15px;
            padding-top: 15px;
            border-top: 1px solid #e0e0e0;
            font-size: 13px;
            color: #555;
        }
        
        .timeline-content:hover .timeline-details {
            display: block;
        }
        
        .trials-table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            background: white;
            border-radius: 10px;
            overflow: hidden;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .trials-table thead {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
        }
        
        .trials-table th {
            padding: 15px;
            text-align: left;
            font-weight: 600;
        }
        
        .trials-table td {
            padding: 15px;
            border-bottom: 1px solid #e0e0e0;
        }
        
        .trials-table tbody tr:hover {
            background: #f8f9fa;
        }
        
        .trial-phase {
            display: inline-block;
            padding: 4px 10px;
            border-radius: 20px;
            font-size: 12px;
            font-weight: 600;
        }
        
        .phase-1 { background: #e3f2fd; color: #1976d2; }
        .phase-2 { background: #f3e5f5; color: #7b1fa2; }
        .phase-3 { background: #e8f5e9; color: #388e3c; }
        
        .efficacy-chart {
            background: white;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .chart-title {
            font-size: 20px;
            font-weight: bold;
            margin-bottom: 20px;
            color: #333;
        }
        
        .bar-chart {
            display: flex;
            align-items: flex-end;
            height: 300px;
            gap: 20px;
            padding: 20px 0;
        }
        
        .bar-group {
            flex: 1;
            display: flex;
            flex-direction: column;
            align-items: center;
            justify-content: flex-end;
        }
        
        .bar {
            width: 100%;
            background: linear-gradient(180deg, #667eea 0%, #764ba2 100%);
            border-radius: 10px 10px 0 0;
            position: relative;
            transition: all 0.3s;
            cursor: pointer;
        }
        
        .bar:hover {
            transform: scaleY(1.05);
            box-shadow: 0 5px 20px rgba(102, 126, 234, 0.3);
        }
        
        .bar-value {
            position: absolute;
            top: -30px;
            left: 50%;
            transform: translateX(-50%);
            font-weight: bold;
            font-size: 18px;
            color: #667eea;
        }
        
        .bar-label {
            margin-top: 10px;
            text-align: center;
            font-size: 14px;
            color: #666;
        }
        
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 20px;
            margin: 20px 0;
        }
        
        .safety-card {
            background: linear-gradient(135deg, #fff 0%, #f8f9fa 100%);
            border: 2px solid #e0e0e0;
            border-radius: 12px;
            padding: 20px;
            text-align: center;
            transition: all 0.3s;
        }
        
        .safety-card:hover {
            transform: translateY(-5px);
            box-shadow: 0 10px 30px rgba(0,0,0,0.1);
        }
        
        .safety-percentage {
            font-size: 36px;
            font-weight: bold;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }
        
        .safety-label {
            font-size: 14px;
            color: #666;
            margin-top: 10px;
        }
        
        .commercial-section {
            background: #f8f9fa;
            border-radius: 15px;
            padding: 30px;
            margin: 20px 0;
        }
        
        .price-estimate {
            font-size: 32px;
            font-weight: bold;
            color: #667eea;
            margin: 20px 0;
        }
        
        .market-projection {
            display: flex;
            align-items: center;
            gap: 20px;
            margin: 20px 0;
        }
        
        .projection-value {
            font-size: 24px;
            font-weight: bold;
            color: #333;
        }
        
        .projection-label {
            font-size: 14px;
            color: #666;
        }
        
        .pipeline-timeline {
            position: relative;
            padding: 20px 0;
            margin: 30px 0;
        }
        
        .pipeline-track {
            height: 8px;
            background: #e0e0e0;
            border-radius: 4px;
            position: relative;
        }
        
        .pipeline-progress {
            height: 100%;
            background: linear-gradient(90deg, #667eea 0%, #764ba2 100%);
            border-radius: 4px;
            width: 45%;
            position: relative;
            animation: progressGrow 2s ease-out;
        }
        
        @keyframes progressGrow {
            from { width: 0; }
        }
        
        .pipeline-milestone {
            position: absolute;
            top: -40px;
            transform: translateX(-50%);
            text-align: center;
            white-space: nowrap;
        }
        
        .milestone-dot {
            width: 16px;
            height: 16px;
            background: white;
            border: 3px solid #667eea;
            border-radius: 50%;
            margin: 0 auto 5px;
        }
        
        .milestone-label {
            font-size: 12px;
            color: #666;
        }
        
        .info-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(300px, 1fr));
            gap: 30px;
            margin: 30px 0;
        }
        
        .info-card {
            background: white;
            border-radius: 15px;
            padding: 25px;
            box-shadow: 0 5px 20px rgba(0,0,0,0.1);
        }
        
        .info-card-title {
            font-size: 18px;
            font-weight: bold;
            color: #333;
            margin-bottom: 15px;
            display: flex;
            align-items: center;
        }
        
        .info-icon {
            width: 30px;
            height: 30px;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            margin-right: 10px;
            color: white;
            font-size: 14px;
        }
        
        .info-list {
            list-style: none;
        }
        
        .info-list li {
            padding: 8px 0;
            border-bottom: 1px solid #f0f0f0;
            color: #666;
            font-size: 14px;
        }
        
        .info-list li:last-child {
            border-bottom: none;
        }
        
        .highlight-box {
            background: linear-gradient(135deg, rgba(102, 126, 234, 0.1) 0%, rgba(118, 75, 162, 0.1) 100%);
            border-left: 4px solid #667eea;
            padding: 20px;
            border-radius: 8px;
            margin: 20px 0;
        }
        
        .highlight-title {
            font-weight: bold;
            color: #667eea;
            margin-bottom: 10px;
        }
        
        .highlight-content {
            color: #555;
            line-height: 1.6;
        }
        
        @media (max-width: 768px) {
            .timeline-item {
                flex-direction: column !important;
            }
            
            .timeline-content {
                width: 90%;
                margin: 0 auto;
            }
            
            .timeline-line {
                left: 20px;
            }
            
            .timeline-dot {
                left: 20px;
            }
            
            .bar-chart {
                height: 200px;
            }
        }
    </style>
</head>
<body>
    
    <div class="container">
        <div class="header">
            <div class="drug-title">
                <div class="drug-name">AZD0780</div>
                <div class="drug-subtitle">Oral PCSK9 Inhibitor (Small Molecule)</div>
                <div class="drug-company">AstraZeneca</div>
                <span class="status-badge">Phase III Ongoing (2025)</span>
            </div>
        </div>
        
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('mechanism')">Mechanism & Dosing</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory Timeline</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Trials</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety Profile</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
            <button class="nav-tab" onclick="showTab('pipeline')">Pipeline & Future</button>
        </div>
        
        <div class="content-area">
            <!-- Overview Tab -->
            <div id="overview" class="tab-content active">
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üî¨</div>
                            Key Features
                        </div>
                        <ul class="info-list">
                            <li>First true oral small molecule PCSK9 inhibitor</li>
                            <li>Once-daily dosing (30 mg)</li>
                            <li>No meal restrictions required</li>
                            <li>~50% LDL-C reduction achieved</li>
                            <li>UK Innovation Passport (2023)</li>
                            <li>Potential neuroprotective effects</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üìä</div>
                            Clinical Highlights
                        </div>
                        <ul class="info-list">
                            <li>Phase IIb PURSUIT: 50.7% LDL reduction</li>
                            <li>84% patients achieved LDL <70 mg/dL</li>
                            <li>Consistent efficacy across statin intensities</li>
                            <li>PCSK9 reduction >90%</li>
                            <li>Phase III trials recruiting (n>13,000)</li>
                            <li>MACE outcomes trial through 2029</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Position
                        </div>
                        <ul class="info-list">
                            <li>Part of AZ's $80B CVRM portfolio target</li>
                            <li>Menarini partnership for EU distribution</li>
                            <li>Fixed-dose combinations in development</li>
                            <li>Competing with Merck's MK-0616</li>
                            <li>Projected $1-5B market by 2030</li>
                            <li>Patent protection to late 2030s</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Unique Differentiation</div>
                    <div class="highlight-content">
                        AZD0780 stands out as the first traditional small molecule PCSK9 inhibitor (vs peptide-based competitors), 
                        with potential advantages in manufacturing scalability and tissue distribution. Preliminary data showing 
                        reduction in Alzheimer's biomarkers (CSF p-tau217) suggests possible neuroprotective benefits beyond 
                        cardiovascular effects, though this remains exploratory.
                    </div>
                </div>
            </div>
            
            <!-- Mechanism & Dosing Tab -->
            <div id="mechanism" class="tab-content">
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">‚öôÔ∏è</div>
                        Mechanism of Action
                    </div>
                    <div class="mechanism-content">
                        AZD0780 is an investigational <span class="mechanism-highlight">oral small-molecule inhibitor of PCSK9</span>. 
                        It binds with high affinity to the <span class="mechanism-highlight">C-terminal domain of PCSK9</span>, 
                        stabilizing the PCSK9-LDL receptor (LDL-R) complex and preventing PCSK9-mediated lysosomal degradation 
                        of LDL-R on hepatocytes. This unique mechanism allows for:
                        <ul style="margin-top: 15px; margin-left: 20px;">
                            <li>Increased recycling and surface expression of LDL-R</li>
                            <li>Enhanced hepatic uptake and clearance of LDL-C</li>
                            <li>Substantial reductions in serum LDL-C levels (~50%)</li>
                            <li>>90% reduction in free PCSK9 levels</li>
                        </ul>
                        Unlike macrocyclic peptides (e.g., MK-0616), AZD0780 is a <span class="mechanism-highlight">traditional small molecule</span>, 
                        potentially offering advantages in manufacturing scalability and tissue distribution. Its extracellular 
                        action minimizes off-target intracellular effects seen with some lipid therapies.
                    </div>
                </div>
                
                <div class="mechanism-section">
                    <div class="mechanism-title">
                        <div class="mechanism-icon">üíä</div>
                        Dosing Information
                    </div>
                    <div class="dosing-grid">
                        <div class="dosing-card">
                            <div class="dosing-label">Administration</div>
                            <div class="dosing-value">Oral, QD</div>
                            <div class="dosing-detail">Once-daily tablet</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Primary Dose</div>
                            <div class="dosing-value">30 mg</div>
                            <div class="dosing-detail">Phase IIb optimal dose</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Dose Range</div>
                            <div class="dosing-value">5-60 mg</div>
                            <div class="dosing-detail">Evaluated in trials</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Food Requirements</div>
                            <div class="dosing-value">None</div>
                            <div class="dosing-detail">Can be taken without meals</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Onset</div>
                            <div class="dosing-value">2 weeks</div>
                            <div class="dosing-detail">LDL-C reduction begins</div>
                        </div>
                        <div class="dosing-card">
                            <div class="dosing-label">Steady State</div>
                            <div class="dosing-value">4-12 weeks</div>
                            <div class="dosing-detail">Full effect achieved</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Dosing Advantages</div>
                    <div class="highlight-content">
                        No dose adjustments needed for renal/hepatic impairment based on available data. High bioavailability 
                        unaffected by food enhances patient convenience. Daily dosing prioritizes patient autonomy compared to 
                        inclisiran's biannual injections, though relies on adherence for sustained effects.
                    </div>
                </div>
            </div>
            
            <!-- Regulatory Timeline Tab -->
            <div id="regulatory" class="tab-content">
                <div class="timeline-container">
                    <div class="timeline-header">FDA/EMA Regulatory Timeline</div>
                    <div class="timeline">
                        <div class="timeline-line"></div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Pre-2023</div>
                                <div class="timeline-title">Preclinical Development</div>
                                <div class="timeline-description">Optimization of small-molecule scaffold for oral bioavailability</div>
                                <div class="timeline-details">
                                    Focus on developing a traditional small molecule with high oral bioavailability 
                                    and PCSK9 binding affinity. Extensive preclinical safety and efficacy studies.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2023</div>
                                <div class="timeline-title">Phase I Initiation & UK Innovation Passport</div>
                                <div class="timeline-description">Single/multiple ascending doses in healthy and hypercholesterolemia patients</div>
                                <div class="timeline-details">
                                    52% LDL-C reduction achieved on top of rosuvastatin. UK MHRA granted Innovation Passport 
                                    under ILAP to expedite development and access.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May 29, 2024</div>
                                <div class="timeline-title">Phase I Results Presented</div>
                                <div class="timeline-description">ESC 2024 presentation, advancement to Phase II</div>
                                <div class="timeline-details">
                                    Positive safety and efficacy data presented at European Society of Cardiology. 
                                    Decision to advance to Phase II trials based on promising results.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">March 31, 2025</div>
                                <div class="timeline-title">Phase IIb PURSUIT Results</div>
                                <div class="timeline-description">Topline results announced at ACC 2025</div>
                                <div class="timeline-details">
                                    50.7% LDL reduction confirmed. 84% of patients achieved guideline goals. 
                                    Regulatory consultations with FDA and EMA ongoing.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">May-June 2025</div>
                                <div class="timeline-title">Phase III Program Launch</div>
                                <div class="timeline-description">Multiple Phase III trials initiated</div>
                                <div class="timeline-details">
                                    D7960C00012 (ASCVD/high-risk), NCT07000123 (HeFH), D7960C00013 (HeFH/ASCVD), 
                                    and D7960C00015 (MACE outcomes) trials started. Total enrollment >13,000 patients.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">Mid-2027 (Projected)</div>
                                <div class="timeline-title">NDA/MAA Filing</div>
                                <div class="timeline-description">Regulatory submission based on LDL data</div>
                                <div class="timeline-details">
                                    Expected filing with FDA and EMA based on Phase III LDL-C reduction data. 
                                    Potential EMA-first strategy via Menarini partnership.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                        
                        <div class="timeline-item">
                            <div class="timeline-content">
                                <div class="timeline-date">2029 (Projected)</div>
                                <div class="timeline-title">MACE Outcomes Data</div>
                                <div class="timeline-description">Phase III outcomes trial completion</div>
                                <div class="timeline-details">
                                    D7960C00015 trial with 10,000 patients expected to provide definitive MACE data. 
                                    Will support expanded indications and broader reimbursement.
                                </div>
                            </div>
                            <div class="timeline-dot"></div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Regulatory Strategy</div>
                    <div class="highlight-content">
                        Development has advanced steadily without reported clinical holds, CRLs, or significant delays. 
                        Focus on LDL-C surrogates for initial submissions, similar to prior PCSK9 therapies. 
                        Potential EMA-first strategy due to European partnerships. Innovation Passport from UK MHRA 
                        provides expedited pathway in UK market.
                    </div>
                </div>
            </div>
            
            <!-- Clinical Trials Tab -->
            <div id="clinical" class="tab-content">
                <table class="trials-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>Population</th>
                            <th>N</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td>Phase I<br><small>2023-2024</small></td>
                            <td><span class="trial-phase phase-1">Phase I</span></td>
                            <td>Healthy/Hypercholesterolemia</td>
                            <td>~100</td>
                            <td>Safety/PK/PD</td>
                            <td>52% LDL-C reduction on rosuvastatin<br>Total ~78% from baseline<br>PCSK9 >90% reduction</td>
                        </tr>
                        <tr>
                            <td>Phase IIa<br><small>2024</small></td>
                            <td><span class="trial-phase phase-2">Phase II</span></td>
                            <td>Add-on to statins</td>
                            <td>~60</td>
                            <td>% LDL-C change at week 12</td>
                            <td>~52% reduction achieved</td>
                        </tr>
                        <tr>
                            <td>PURSUIT<br><small>NCT06173570</small></td>
                            <td><span class="trial-phase phase-2">Phase IIb</span></td>
                            <td>Hyperlipidemia</td>
                            <td>428</td>
                            <td>% LDL-C change at week 12</td>
                            <td>50.7% reduction (30 mg)<br>84% achieved <70 mg/dL<br>ApoB/non-HDL-C ~40-50%<br>Lp(a) ~20%, hsCRP reduced</td>
                        </tr>
                        <tr>
                            <td>D7960C00012<br><small>NCT07000136</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>ASCVD/High-risk</td>
                            <td>~2,500</td>
                            <td>% LDL-C change at week 24</td>
                            <td>Ongoing (Started May 2025)</td>
                        </tr>
                        <tr>
                            <td>D7960C00013<br><small>NCT07000123</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>HeFH/ASCVD</td>
                            <td>~300</td>
                            <td>% LDL-C change at week 24</td>
                            <td>Ongoing (Started June 2025)</td>
                        </tr>
                        <tr>
                            <td>D7960C00015<br><small>NCT07000357</small></td>
                            <td><span class="trial-phase phase-3">Phase III</span></td>
                            <td>ASCVD</td>
                            <td>~10,000</td>
                            <td>MACE (CV death, MI, stroke)</td>
                            <td>Ongoing (Ends ~2029)</td>
                        </tr>
                    </tbody>
                </table>
                
                <div class="efficacy-chart">
                    <div class="chart-title">LDL-C Reduction Across Trials</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 52%;">
                                <div class="bar-value">52%</div>
                            </div>
                            <div class="bar-label">Phase I<br>+Rosuvastatin</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 78%;">
                                <div class="bar-value">78%</div>
                            </div>
                            <div class="bar-label">Phase I<br>Total from Baseline</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 52%;">
                                <div class="bar-value">52%</div>
                            </div>
                            <div class="bar-label">Phase IIa<br>Week 12</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 50.7%;">
                                <div class="bar-value">50.7%</div>
                            </div>
                            <div class="bar-label">PURSUIT<br>30mg Dose</div>
                        </div>
                    </div>
                </div>
                
                <div class="efficacy-chart">
                    <div class="chart-title">Secondary Endpoints - PURSUIT Trial</div>
                    <div class="bar-chart">
                        <div class="bar-group">
                            <div class="bar" style="height: 45%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">45%</div>
                            </div>
                            <div class="bar-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 45%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">45%</div>
                            </div>
                            <div class="bar-label">Non-HDL-C<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 20%; background: linear-gradient(180deg, #4caf50 0%, #2e7d32 100%);">
                                <div class="bar-value">20%</div>
                            </div>
                            <div class="bar-label">Lp(a)<br>Reduction</div>
                        </div>
                        <div class="bar-group">
                            <div class="bar" style="height: 84%; background: linear-gradient(180deg, #ff9800 0%, #f57c00 100%);">
                                <div class="bar-value">84%</div>
                            </div>
                            <div class="bar-label">Patients<br><70 mg/dL</div>
                        </div>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Exploratory Finding: Neuroprotective Potential</div>
                    <div class="highlight-content">
                        Preliminary data from BROADWAY trial substudy showed reduction in cerebrospinal fluid phospho-tau217 
                        biomarkers, suggesting potential neuroprotective effects via brain PCSK9 modulation. While exploratory, 
                        this could differentiate AZD0780 if further research confirms cognitive benefits.
                    </div>
                </div>
            </div>
            
            <!-- Safety Tab -->
            <div id="safety" class="tab-content">
                <div class="safety-grid">
                    <div class="safety-card">
                        <div class="safety-percentage">38.2%</div>
                        <div class="safety-label">Overall AEs (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">32.6%</div>
                        <div class="safety-label">Overall AEs (Placebo)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">3%</div>
                        <div class="safety-label">Serious AEs (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">6%</div>
                        <div class="safety-label">Serious AEs (Placebo)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">1.5%</div>
                        <div class="safety-label">Discontinuation (Drug)</div>
                    </div>
                    <div class="safety-card">
                        <div class="safety-percentage">2.3%</div>
                        <div class="safety-label">Discontinuation (Placebo)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            Common Adverse Events (>5%)
                        </div>
                        <ul class="info-list">
                            <li>Headache (6-8%)</li>
                            <li>Nausea (4-6%, mild)</li>
                            <li>Diarrhea (4-6%, mild)</li>
                            <li>All mild to moderate severity</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚úì</div>
                            No Safety Signals
                        </div>
                        <ul class="info-list">
                            <li>No liver enzyme elevations</li>
                            <li>No CK elevations</li>
                            <li>No glucose/glycemic effects</li>
                            <li>No blood pressure increases</li>
                            <li>No myalgia signals</li>
                            <li>No neurocognitive effects</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚ÑπÔ∏è</div>
                            Low LDL-C Safety
                        </div>
                        <ul class="info-list">
                            <li>~20% achieved LDL <25 mg/dL</li>
                            <li>No cognitive adverse events</li>
                            <li>Class meta-analyses show no impairment</li>
                            <li>Safe even with LDL <15 mg/dL over 5+ years</li>
                            <li>Brain lipids preserved with PCSK9 inhibition</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Safety Profile Summary</div>
                    <div class="highlight-content">
                        AZD0780 exhibits a favorable safety profile comparable to placebo, with ~1,000 patients exposed by 2025. 
                        No black-box warnings projected. Small-molecule nature avoids immunogenicity issues of antibodies, 
                        and extracellular action limits organ toxicity. No renal effects or organ-specific toxicity expected. 
                        Post-Phase III monitoring planned for rare events.
                    </div>
                </div>
            </div>
            
            <!-- Commercial Tab -->
            <div id="commercial" class="tab-content">
                <div class="commercial-section">
                    <div class="price-estimate">$4,000 - $6,000/year</div>
                    <div style="color: #666; margin-bottom: 30px;">Projected annual cost (potentially discounted for volume vs. injectables)</div>
                    
                    <div class="market-projection">
                        <div>
                            <div class="projection-value">$1-5 Billion</div>
                            <div class="projection-label">Market potential by 2030</div>
                        </div>
                        <div>
                            <div class="projection-value">70-80%</div>
                            <div class="projection-label">Expected PA denial rate initially</div>
                        </div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üí∞</div>
                            Payer Considerations
                        </div>
                        <ul class="info-list">
                            <li>Initially restricted to high-risk/statin-intolerant</li>
                            <li>Similar PA requirements to mAbs expected</li>
                            <li>Pharmacy benefit eases access vs. medical</li>
                            <li>Outcomes data key for broader coverage</li>
                            <li>Volume-based pricing negotiations likely</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üè•</div>
                            Market Access Strategy
                        </div>
                        <ul class="info-list">
                            <li>Broader GP use vs. specialist-only injectables</li>
                            <li>Adherence programs needed for daily dosing</li>
                            <li>Fixed-dose combinations for convenience</li>
                            <li>Potential rosuvastatin/ezetimibe combos</li>
                            <li>Menarini partnership for EU distribution</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Competitive Positioning
                        </div>
                        <ul class="info-list">
                            <li>Competing with Merck's MK-0616</li>
                            <li>Small molecule vs. peptide differentiation</li>
                            <li>Part of AZ's CV portfolio bundling</li>
                            <li>Potential neuro indication differentiation</li>
                            <li>Manufacturing scalability advantage</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Commercial Outlook</div>
                    <div class="highlight-content">
                        As orals enter market, potential to disrupt inclisiran's position if priced competitively. 
                        Daily pill format favors primary care adoption but requires adherence focus. AZ's existing 
                        CV portfolio (including potential obicetrapib CETP inhibitor) enables bundling strategies. 
                        By 2030, oral PCSK9 inhibitors may dominate market, with AZD0780's small molecule nature 
                        and combination potential supporting its niche in multi-drug regimens.
                    </div>
                </div>
            </div>
            
            <!-- Pipeline Tab -->
            <div id="pipeline" class="tab-content">
                <div class="pipeline-timeline">
                    <div class="pipeline-track">
                        <div class="pipeline-progress"></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 0;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Preclinical</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 20%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase I</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 35%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Phase II</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 45%;">
                        <div class="milestone-dot" style="background: #667eea;"></div>
                        <div class="milestone-label"><strong>Phase III (Current)</strong></div>
                    </div>
                    <div class="pipeline-milestone" style="left: 70%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">Approval (2027)</div>
                    </div>
                    <div class="pipeline-milestone" style="left: 100%;">
                        <div class="milestone-dot"></div>
                        <div class="milestone-label">MACE Data (2029)</div>
                    </div>
                </div>
                
                <div class="info-grid">
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üîÆ</div>
                            Future Development
                        </div>
                        <ul class="info-list">
                            <li>Fixed-dose combinations with statins/ezetimibe</li>
                            <li>Potential neuro indications (tau biomarkers)</li>
                            <li>Part of AZ's $80B CVRM revenue target</li>
                            <li>Integration with obicetrapib (CETP inhibitor)</li>
                            <li>Single-pill multi-mechanism therapy</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">‚öîÔ∏è</div>
                            Competitive Landscape 2030
                        </div>
                        <ul class="info-list">
                            <li>Multiple oral PCSK9 options expected</li>
                            <li>Competition from gene therapies (Verve)</li>
                            <li>Generics post-patent (late 2030s)</li>
                            <li>Inclisiran/mAbs relegated to niches</li>
                            <li>Triple therapy for highest-risk patients</li>
                        </ul>
                    </div>
                    
                    <div class="info-card">
                        <div class="info-card-title">
                            <div class="info-icon">üéØ</div>
                            Strategic Differentiation
                        </div>
                        <ul class="info-list">
                            <li>Small molecule vs. peptide competitors</li>
                            <li>Manufacturing scalability advantage</li>
                            <li>Broader tissue distribution potential</li>
                            <li>Portfolio synergies with AZ CV drugs</li>
                            <li>Possible cognitive benefit claims</li>
                        </ul>
                    </div>
                </div>
                
                <div class="highlight-box">
                    <div class="highlight-title">Long-term Outlook</div>
                    <div class="highlight-content">
                        By 2030, oral PCSK9 inhibitors likely to dominate market, potentially displacing injectable 
                        options for most patients. AZD0780's differentiation through small molecule nature, combination 
                        potential, and possible neuroprotective effects positions it well in multi-drug regimens. 
                        Patent protection to late 2030s provides sustainability window before generic entry. Success 
                        depends on outcomes data, pricing strategy, and ability to compete with Merck's first-mover 
                        advantage.
                    </div>
                </div>
            </div>
        </div>
    </div>
    
    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active class from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Add active class to clicked nav tab
            event.target.classList.add('active');
        }
    </script>
</body>
</html>